Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AES 2022 | Neocortical depth leads for RNS in drug refractory epilepsy

The Responsive Neurostimulation (RNS) system has been approved by the FDA to treat focal or partial seizures in adults with drug refractory epilepsy. During clinical development, the use of cortical strip leads was more common in patients with neocortical seizure foci, but as the use of stereoelectroencephalography (sEEG) has grown, placing RNS system depth leads has become more common. Sina Sadeghzadeh, Medical Student, Stanford University School of Medicine, Stanford, CA, talks on his retrospective chart review study assessing outcomes in patients treated with the RNS system with depth leads in the neocortex. Of the 53 patients included in the study, 33 had additional depth leads in a non-neocortical focus and 12 had an additional neocortical strip lead. A median seizure reduction of 75% was recorded at last follow-up (median 2.2 years). Safety was shown to be consistent with deep brain electrode placement for movement disorders. Overall, Mr Sadeghzadeh notes that depth leads may be the preferred option for RNS following sEEG or if strip lead placement poses increased surgical risk. This interview took place at the American Epilepsy Society (AES) Annual Meeting 2022 in Nashville, TN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.